Nereid Therapeutics, a US-based biotechnology company, announced on Monday that it has named Michael Kauffman, MD, PhD as its new president and chief executive officer.
Dr Kauffman is also joining the Nereid board of directors. He has three decades of experience and has headed organisations through the discovery, development, and commercialisation of novel drugs. He has spent over a decade as CEO and co-founder of Karyopharm and clinical consultant for the Kyprolis approval at Onyx Pharmaceuticals (subsequently acquired by Amgen). He has also worked as a board member and then CMO of Proteolix, operating partner at Bessemer Venture Partners, and CEO of Epix Pharmaceuticals and Predix Pharmaceuticals. He has served in leadership positions at Millennium Pharmaceuticals and Biogen. Presently, he chairs the boards of BiVictriX Therapeutics and Incendia Therapeutics and serves on the boards of Verastem Oncology, Kezar Life Sciences and Adicet Bio.
Dr Kauffman said: "This is a transformational time to join Nereid as we enter a new phase of development and advance multiple programs in oncology and neurodegeneration towards the clinic. I look forward to working alongside this highly talented team who are pioneers in the novel, exciting and highly physiologically relevant field of biomolecular condensate science, which is the core of Nereid's approach to drug discovery and development."
Renew Biotechnologies names new chief operating officer
Teva, Sanofi accelerate inflammatory bowel disease drug trial
Ro adds David B Allison to Advisory Board
Charles River Laboratories and Autobahn Labs forge alliance to boost academic drug discovery
Nkarta partnering with Columbia on investigator-led lupus trial for NKX019
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Anixa Biosciences' ovarian cancer CAR-T therapy individual patient IND receives FDA approval
Evergreen Nephrology names new director
Emmaus Life Sciences names new chief executive officer
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
TC BioPharm (Holdings) doses sixth patient in TCB-008 clinical trial
Caidya names new chief executive officer
Ionis Pharmaceuticals reports positive results for ION582 in Angelman syndrome study
Nuvalent launches HEROEX-1 trial for HER2-selective inhibitor NVL-330
Astellas and Osaka University collaborate on stem cell therapy for disc degeneration